ABT-751 in Treating Children With Neuroblastoma That Has Relapsed or Not Responded to Previous Treatment

Trial ID or NCT#

NCT00436852

Status

not recruiting iconNOT RECRUITING

Purpose

This phase II trial is studying how well ABT-751 works in treating children with neuroblastoma that has relapsed or not responded to previous treatment. Drugs used in chemotherapy, such as ABT-751, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.

Official Title

A Phase II Study of ABT-751, an Orally Bioavailable Tubulin Binding Agent, in Children With Relapsed or Refractory Neuroblastoma

Eligibility Criteria

Ages Eligible for Study: Younger than 21 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Show Less

Investigator(s)

Neyssa Marina

Contact us to find out if this trial is right for you.

Contact

Neyssa Marina
6507235535

View on ClinicalTrials.gov